Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07177196 · ClinicalTrials.gov registry record · Phase 1
Personalized Antisense Oligonucleotide Therapy for a Single Participant With PRPH2 Mutation Associated With Retinal Dystrophy
A Phase 1 study of Retinal Dystrophy, sponsored by n-Lorem Foundation.
- Active
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
- 1
- Study location
NCT07177196 is a Phase 1 study of Retinal Dystrophy that is active but no longer recruiting, run by n-Lorem Foundation. The registered enrollment target is 1 participants, below the 37-participant average among 3 other Retinal Dystrophy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07177196, a Phase 1 study of Retinal Dystrophy, is active but no longer recruiting, sponsored by n-Lorem Foundation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with Retinal Dystrophy due to PRPH2 mutation
Conditions Studied
Interventions
- DRUG nL-PRPH2-001
Study Locations (1)
California
- University of California San Diego - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2025-08-28 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07177196
The ClinicalTrials.gov registry entry for NCT07177196 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 37-participant average among 3 other Retinal Dystrophy trials with a reported enrollment target (97% lower). The listed sponsor is n-Lorem Foundation, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Retinal Dystrophy appearing as the primary indexed condition, and to 1 intervention - of which nL-PRPH2-001 is the first listed.
NCT07177196 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07177196 about?
NCT07177196 is a clinical study titled "Personalized Antisense Oligonucleotide Therapy for a Single Participant With PRPH2 Mutation Associated With Retinal Dystrophy". This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with Retinal Dystrophy due to PRPH2 mutation
What is the current status of trial NCT07177196?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2025-08-28. Estimated completion is 2027-08.
What conditions does trial NCT07177196 study?
This clinical trial studies the following conditions: Retinal Dystrophy.
What interventions are being tested in trial NCT07177196?
The interventions under investigation include: nL-PRPH2-001 (DRUG).
Who is sponsoring clinical trial NCT07177196?
This trial is sponsored by n-Lorem Foundation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07177196 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinal Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.